Skip to content

Helen Torley, President and CEO at Halozyme Therapeutics, sold HALO on Sep 11, 2026

Data as of Oct 16

▼ SELL$485K4,508 shares at $107.55Helen Torley President and CEOHALO Halozyme Therapeutics, Inc.
Watch HALO
Traded
Sep 11, 2026
Disclosed
Sep 11, 2026
Filed
The same day

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Helen Torley, President and CEO at Halozyme Therapeutics, sold HALO on Sep 11, 2026TRADEDDISCLOSED
HALOSimilar stocks (XLV — its sector index fund), rebased to HALO's price on the disclosure day
HALO since disclosure
+13.7%
after the sale
Similar stocks (XLV) since disclosure
+6.9%
XLV — its sector index fund

Change in closing price from Sep 11, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLHelen Torley President and CEOHALO Halozyme Therapeutics, Inc.$1.7Mdisclosed Sep 11 · filed the same day
  2. ▼ SELLHelen Torley President and CEOHALO Halozyme Therapeutics, Inc.$1.6Mdisclosed Sep 11 · filed 1 day after the trade
  3. ▼ SELLHelen Torley President and CEOHALO Halozyme Therapeutics, Inc.$582Kdisclosed Sep 11 · filed 1 day after the trade
  4. ▼ SELLHelen Torley President and CEOHALO Halozyme Therapeutics, Inc.$711Kdisclosed Sep 11 · filed 2 days after the trade
  5. ▼ SELLHelen Torley President and CEOHALO Halozyme Therapeutics, Inc.$10.9Kdisclosed Sep 11 · filed 2 days after the trade
  6. ▼ SELLHelen Torley President and CEOHALO Halozyme Therapeutics, Inc.$1.4Mdisclosed Sep 11 · filed 2 days after the trade

See every trade on HALO →